<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979378</url>
  </required_header>
  <id_info>
    <org_study_id>CATSSO</org_study_id>
    <nct_id>NCT03979378</nct_id>
  </id_info>
  <brief_title>Treatment of Ectopic Calcification / Ossification With Sodium Thiosulfate (CATSSO)</brief_title>
  <official_title>Treatment of Ectopic Calcification / Ossification With Sodium Thiosulfate (CATSSO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      Ectopic calcification and ossification complicate many diseases, which are rare for the most&#xD;
      part. These calcifications (or ossifications) are generally classified according to their&#xD;
      apparent formation mechanism. Even if very different diseases can be at the origin, these&#xD;
      calcifications (or ossifications) have as common points: an unknown physiopathology, a&#xD;
      composition of calcium pyrophosphate for the most part and l no curative treatment validated&#xD;
      to date.&#xD;
&#xD;
      Indeed, although several reported cases suggest the potential efficacy of different&#xD;
      treatments , none of these treatments is currently recognized as effective because of the&#xD;
      absence of confirmation data or because of contradictory results.&#xD;
&#xD;
      Sodium thiosulfate (STS) has been used for a long time as an antidote to cyanide poisoning&#xD;
      and as a protective agent against cytotoxic side effects such as ifosphamide. More recently,&#xD;
      STS has been reported in the treatment of renal calcification. vascular or even subcutaneous.&#xD;
      First prospective studies on animal models and in humans seem to confirm the interest of this&#xD;
      product in the treatment of these abnormal calcifications.&#xD;
&#xD;
      For several months, a magistral preparation in the form of ointment based on STS has been&#xD;
      developed by the pharmacy of Limoges University Hospital in order to combine the local effect&#xD;
      of STS while avoiding the side effects of an administration of this treatment by systemic&#xD;
      way. The first uses of this preparation appear promising and some preliminary results have&#xD;
      already been published. The benefit / risk ratio of this approach seems to be advantageous&#xD;
      for clinicians since preparations whose composition is close are currently validated by the&#xD;
      FDA and the World Health Organisation for the treatment of benign pathologies such as&#xD;
      cutaneous dermatophytes or pityriasis versicolor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calcification/Ossification volume</measure>
    <time_frame>Month 6</time_frame>
    <description>Percentage decrease in the volume or surface area of calcifications (or ossification) treated on imaging of the same type performed before and 6 months after dermal STS use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aesthetic evolution from baseline at 6 month</measure>
    <time_frame>Day 0, Month 6</time_frame>
    <description>aesthetic evolution on picture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain from baseline at 6 month</measure>
    <time_frame>Day 0, Month 6</time_frame>
    <description>Evaluation of pain with scale VAE (visual analog evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the quality of life from baseline at 6 month</measure>
    <time_frame>Day 0, Month 6</time_frame>
    <description>evolution of the quality of life with Skindex scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local or general side effects</measure>
    <time_frame>Month 6</time_frame>
    <description>Number and nature of local or general side effects</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sodium Thiosulfate</condition>
  <condition>Ectopic Ossification</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patient with ectopic calcification / ossification&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any patient treated with sodium thiosulfate dermally provided by the pharmacy of&#xD;
             Limoges University Hospital.&#xD;
&#xD;
          -  availability of an objective imaging evaluation to compare the volume or surface of&#xD;
             calcifications (or ossifications) treated (on two orthogonal incidences) before and&#xD;
             after 6 months of treatment application.&#xD;
&#xD;
          -  consent to participation in the study signed by the patient or by one of the holders&#xD;
             of parental authority in the case of a minor patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  calcification with concomitant cutaneous rupture which can allow an externalization of&#xD;
             the calcium material by mechanical effects.&#xD;
&#xD;
          -  Patient with calcification secondary to one of the following pathologies:&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  chronic renal failure&#xD;
&#xD;
          -  iatrogenic origin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grenoble university hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHABRE, MD</last_name>
      <email>olivier.chabre@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CHABRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicetre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Linglart, MD</last_name>
      <email>agnes.linglart@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Agnes Linglart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent GUIGONIS, MD</last_name>
      <email>vincent.guigoni@unilim.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire BAHANS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Vincent GUIGONIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie COURBEBAISSE, MD</last_name>
      <email>marie.courbebaisse@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie COURBEBAISSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lariboisière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Korng EA, MD</last_name>
      <email>korng.ea@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Korng EA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine BODEMER, MD</last_name>
      <email>christine.bodemer@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christine BODEMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Debré Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOURRAT</last_name>
      <email>emmanuelle.bourrat@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOURRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
    <mesh_term>Ossification, Heterotopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

